Rehabilitation for Addicted Prisoners Trust

RAPT Therapeutics Announces Management Promotions

Retrieved on: 
Wednesday, March 4, 2020
Rapt, Rehabilitation for Addicted Prisoners Trust

Both Paul and Lisa continue to make incredible contributions to RAPTs success in setting and implementing strategic business and scientific plans, said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics.

Key Points: 
  • Both Paul and Lisa continue to make incredible contributions to RAPTs success in setting and implementing strategic business and scientific plans, said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics.
  • Paul joined RAPT Therapeutics in 2016, as Vice President of Quantitative and Computational Biology.
  • Lisa joined RAPT Therapeutics in 2018, as Senior Director of Business Development and Strategy.
  • Prior to joining RAPT, she served as Director of Alliance Management for Nurix, Inc. where she managed drug discovery and development strategic alliances with pharma partners in addition to management of strategic research collaborations.

Author Ralph Oyague's new book "The Adventures of a Dog Named Sam" is a dramatic rhyming tale featuring a man and his heroic pup for young readers

Retrieved on: 
Friday, January 3, 2020
Rehabilitation for Addicted Prisoners Trust

Oyague writes, "Paragraphs are visually illustrated with a self-contained stylistic story of loyalty, intelligence, and courage of a pet dog.

Key Points: 
  • Oyague writes, "Paragraphs are visually illustrated with a self-contained stylistic story of loyalty, intelligence, and courage of a pet dog.
  • The story evolves in poetic verse to keep a child in rapt attention with a mixture of adventure and word fascination with coincidental development to spark a child's imagination.
  • So, parents, don't be surprised if your children request a repeated rereading of 'The Adventures of a Dog Named Sam' at bedtime and throughout the day.
  • Published by Page Publishing, Ralph Oyague's entertaining book is a wonderful addition to any home- or school-based children's library.

RAPT Therapeutics and Hanmi Pharmaceutical Announce Collaboration to Develop and Commercialize FLX475 in Asia

Retrieved on: 
Tuesday, December 3, 2019
Hanmi Pharmaceutical, Hanmi, Health, Pharmaceutical industry, Rehabilitation for Addicted Prisoners Trust, Pharmaceutical sciences

We look forward to partnering with RAPT to advance FLX475 through the clinic efficiently.

Key Points: 
  • We look forward to partnering with RAPT to advance FLX475 through the clinic efficiently.
  • Under the terms of the agreement, RAPT will receive $10 million in an upfront payment and near-term milestone payment.
  • In return, Hanmi will receive an exclusive license to develop, in parallel with RAPT, and commercialize FLX475 for the treatment of cancer in South Korea and China, including Taiwan and Hong Kong.
  • Hanmi Pharmaceutical is a Korea-based global pharmaceutical company focused on the development and commercialization of new pharmaceutical products.

RAPT Therapeutics Announces Promotion of Key Research and Development Senior Leaders

Retrieved on: 
Monday, July 8, 2019
Oncology, Health, Clinical trials, Pharmaceutical, Biotechnology, Rehabilitation for Addicted Prisoners Trust, Rapt

The leadership and vision that Dirk and Dave have brought to advance the research at RAPT and translate these discoveries into data-driven clinical development programs has been instrumental in achieving our R&D goals, said Brian Wong, M.D., Ph.D., president and CEO of RAPT Therapeutics.

Key Points: 
  • The leadership and vision that Dirk and Dave have brought to advance the research at RAPT and translate these discoveries into data-driven clinical development programs has been instrumental in achieving our R&D goals, said Brian Wong, M.D., Ph.D., president and CEO of RAPT Therapeutics.
  • Dirk joined RAPT Therapeutics in January 2018 from Aduro Biotech, where he served as executive vice president of research and development.
  • Prior to Aduro, Dirk served as the director of research at Anza Therapeutics.
  • David joined RAPT Therapeutics in 2016, bringing more than 20 years of experience in drug discovery.